MORRISVILLE, N.C. — Shares in pharmaceutical firm Trimeris (Nasdaq: TRMS) gained 33 cents on Tuesday after the company announced the latest sales figures for its AIDS drug Fuzeon.

Trimeris shares closed at $8.30, up 33 cents. The stock dropped to a 52-week low of $7.21 last Thursday after Trimeris warned that sales might not meet expectations and that an alternative means of administering Fuzeon by means other than a needle would be delayed.

On Monday, Trimeris said third quarter Fuzeon sales hit $63 million, its best quarterly total since the drug was launched in 2003. The sales total represented an increase of 29 percent more than the same quarter in 2005.

Also Monday, Trimeris reiterated guidance that it would be profitable this year.